Sugi Predict

Sugi Predict / Compounds / SCHEMBL118644

SCHEMBL118644

SCHEMBL118644

COC(=O)CC(=O)C(C)C

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MGAM O43451 2/20 0.50
▸ GAA P10253 2/20 0.50
▸ SI P14410 2/20 0.50
▸ MGAM2 Q2M2H8 2/20 0.50
▸ TSHR P16473 4/20 0.48
▸ HSD17B10 Q99714 3/20 0.43
▸ KMT2A Q03164 2/20 0.36
▸ TET2 Q6N021 1/20 0.36
▸ MEN1 O00255 1/20 0.36
▸ CA12 O43570 2/20 0.35
▸ CA14 Q9ULX7 2/20 0.35
▸ CA7 P43166 1/20 0.35
▸ CA9 Q16790 1/20 0.35
▸ LMNA P02545 2/20 0.34
▸ KDM4E B2RXH2 1/20 0.34
▸ RECQL P46063 1/20 0.34
▸ ALDH1A1 P00352 2/20 0.33
▸ MAPT P10636 2/20 0.33
▸ SMN1; SMN2 Q16637 1/20 0.33
▸ HTT P42858 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28142550 0.85 MGAM (0.68) MGAMGAASIMGAM2TSHR
SCHEMBL443735 0.83 MGAM (0.37) MGAMGAASIMGAM2TSHR
SCHEMBL22089532 0.81 MGAM (0.48) MGAMGAASIMGAM2TSHR
SCHEMBL28239755 0.81 TSHR (0.33) MGAMGAASIMGAM2TSHR
SCHEMBL16624283 0.79 MGAM (0.46) MGAMGAASIMGAM2TSHR
SCHEMBL14421548 0.79 MGAM (0.46) MGAMGAASIMGAM2TSHR
SCHEMBL821105 0.79 MGAM (0.46) MGAMGAASIMGAM2TSHR
SCHEMBL18675306 0.79 MGAM (0.46) MGAMGAASIMGAM2TSHR
SCHEMBL13177852 0.79 GAA (0.46) MGAMGAASIMGAM2TSHR
SCHEMBL3910392 0.79 MGAM (0.46) MGAMGAASIMGAM2TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1452 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250002506-A1 IMPROVED PROCESS FOR THE PREPARATION OF LURBINECTEDIN AND ITS MORPHS THEREOF RK PHARMA INC. (US) 2025-01-02 — — US claimed
CN-118496116-A Method for preparing atorvastatin calcium intermediate through continuous tubular reaction 江苏阿尔法集团盛基药业(宿迁)有限公司 2024-08-16 — — CN claimed
US-12037444-B2 Phenolic resin binder with reduced formaldehyde content ASK CHEMICALS GMBH (DE) 2024-07-16 — — US claimed
CN-115458807-B Multilayer composite electrolyte membrane based on metal-organic frame material and preparation method thereof 华南理工大学 2024-07-09 — — CN claimed
US-20240140969-A1 ANTHRAQUINONE-BASED COVALENT ORGANIC FRAMEWORKS THE HONG KONG UNIVERSITY OF SCIENCE AND TECHNOLOGY (CN) 2024-05-02 — — US claimed
CN-117866203-A Anthraquinone-based covalent organic frameworks 香港科技大学 2024-04-12 — — CN claimed
CN-117695992-A Full-continuous chemical synthesis device and method for atorvastatin calcium mother nucleus 复旦大学 2024-03-15 — — CN claimed
CN-115246772-B Preparation method of isobutyryl methyl acetate 浙江科技学院 2024-02-02 — — CN claimed
CN-113652407-B Carbonyl reductase mutant and application thereof in asymmetric synthesis of chiral compound 浙江工业大学 2024-01-16 — — CN claimed
CN-116655535-A Method for preparing pyrazole pharmaceutical intermediate by adopting micro-flow field reaction technology 南京先进生物材料与过程装备研究院有限公司 2023-08-29 — — CN claimed
CN-101307009-A New synthetic method for (earth)4-fluor-alpha-(2-methyl-1-oxypropyl )-gamma-oxo-N, beta-diphenyl benzene butanamide ZHEJIANG JINGXIN PHARMACEUTICA (CN) 2008-11-19 — — CN claimed
CN-101304967-A Preparation method of (3R,5R) -7- [ 2- (4-fluorophenyl) -5-isopropyl-3-phenyl-4- [ (4-hydroxymethyl phenylamino) carbonyl ] -pyrrole-1-yl ] -3, 5-dihydroxy-heptanoic acid hemicalcium salt RANBAXY LAB LTD (IN) 2008-11-12 — — CN claimed
EP-1978588-A1 Lithium-ion battery electrolytes GM Global Technology Operations, Inc. (US) 2008-10-08 — — EP claimed
US-20080241699-A1 Lithium-Ion Battery Electrolytes GM GLOBAL TECHNOLOGY OPERATIONS, INC. (US) 2008-10-02 — — US claimed
CN-101276939-A Lithium-ion battery electrolytes GM GLOBAL TECH OPERATIONS INC (US) 2008-10-01 — — CN claimed
CN-100412065-C 4-(p-fluorophenyl)-6-isopropyl-2-methylaminopyrimidine-5-methyl formate synthesis method TIANJIN TASLY GROUP CO LTD (CN) 2008-08-20 — — CN claimed
EP-1948598-A1 PROCESS FOR PREPARATION OF (3R, 5R)-7-[2-(4-FLUOROPHENYL)-5-ISOPROPYL-3-PHENYL-4-[(4-HYDROXY METHYL PHENYL AMINO) CARBONYL]-PYRROL-1-YL]-3,5-DIHYDROXY-HEPTANOIC ACID HEMI CALCIUM SALT RANBAXY LABORATORIES, LTD. (IN) 2008-07-30 — — EP claimed
WO-2007054790-A1 PROCESS FOR PREPARATION OF (3R, 5R)-7-[2-(4-FLUOROPHENYL)-5-ISOPROPYL-3-PHENYL-4-[(4-HYDROXY METHYL PHENYL AMINO) CARBONYL]-PYRROL-1-YL]-3,5-DIHYDROXY-HEPTANOIC ACID HEMI CALCIUM SALT RANBAXY LABORATORIES LIMITED (IN) 2007-05-18 — — WO claimed
CN-1733734-A 4-(p-fluorophenyl)-6-isopropyl-2-methylaminopyrimidine-5-methyl formate synthesis method TIANJIN TASLY GROUP CO LTD (CN) 2006-02-15 — — CN claimed
US-5194671-A Process for the preparation of β-ketocarboxylic acid esters WACKER-CHEMIE GMBH (DE) 1993-03-16 — — US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250002506-A1 IMPROVED PROCESS FOR THE PREPARATION OF LURBINECTEDIN AND ITS MORPHS THEREOF RXFP1, REN, CIAPIN1 MGAM 3642/4885GAA 2788/4885SI 280/4885
US-20240140969-A1 ANTHRAQUINONE-BASED COVALENT ORGANIC FRAMEWORKS AURKA, AQP1, AURKB MGAM 3601/4885GAA 2342/4885SI 3769/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.